Suchergebnisse - "Tamura, Tomohide"

PubPharm (33)

1

Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase

enthalten in: Advances in therapy | 2023

von Inui, N. | Toi, Y. | Yoneshima, Y. | +5

2

First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer : Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial

enthalten in: Cancer medicine | 2023

von Kim, H. | Sugawara, S. | Lee, J. | +15

3

A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide : CONSOLE-BC

enthalten in: Cancer | 2022

von Matsuura, K. | Tsurutani, J. | Inoue, K. | +5

4

Prognostic impact of geriatric assessment in elderly patients with non-small cell lung cancer : an integrated analysis of two randomized phase III trials (JCOG1115-A)

enthalten in: Japanese journal of clinical oncology | 2021

von Katayama, H. | Mizusawa, J. | Fukuda, H. | +15

5

Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment : EAST-LC

enthalten in: International journal of clinical oncology | 2019

von Sugawara, S. | Nakagawa, K. | Yamamoto, N. | +19

6

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer : A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2019

von Watanabe, S. | Yoshioka, H. | Sakai, H. | +19

ErratumIn: Lung Cancer. 2019 Jun;132:157-158. - PMID 31014853

7

A dose-finding randomized Phase II study of oral netupitant in combination with palonosetron .75 mg intravenous for the prevention of chemotherapy-induced nausea and vomiting in Japanese patients receiving highly emetogenic chemotherapy

enthalten in: Japanese journal of clinical oncology | 2019

von Osaki, A. | Inoue, K. | Sakai, H. | +9

8

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX) : an open-label, randomised phase 3 trial

enthalten in: Lancet (London, England) | 2017

von Hida, T. | Nokihara, H. | Kondo, M. | +20

CommentIn: Lancet. 2017 Jul 1;390(10089):3-4. - PMID 28501139

9

Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011)

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2017

von Sekine, I. | Harada, H. | Yamamoto, N. | +11

10

Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy

enthalten in: Investigational new drugs | 2017

von Tambo, Y. | Hosomi, Y. | Sakai, H. | +15